Log in to your Inderes Free account to see all free content on this page.

Nanologica

0.37 SEK

+5.43 %

Less than 1K followers

NICA

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

+5.43 %

+0.60 %

-52.28 %

-47.28 %

-68.85 %

-75.99 %

-95.73 %

-97.71 %

-97.95 %

Nanologica is a life science tools company that develops, manufactures and sells advanced input products to pharmaceutical companies. Nanologica's silica-based products are specifically designed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Nanologica operates in a global niche market for drugs for the treatment of diabetes and obesity. Nanologica was founded in 2004 and is headquartered in Södertälje.

Market cap

121.32M SEK

Turnover

93.65K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

20.5.

2026

Interim report Q1'26

28.5.

2026

General meeting '26

27.8.

2026

Interim report Q2'26

All

Press releases

ShowingAll content types

Regulatory press release4 hours ago

Nanologica Announces Outcome of Rights Issue

Regulatory press release3/10/2026, 8:48 AM

The Nomination Committee Proposes Election of Mark Quick and Erik Haeffler as New Board Members of Nanologica AB (publ)

Regulatory press release3/10/2026, 6:48 AM

Nanologica Announces Outcome of Directed Share Issues

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release3/6/2026, 7:28 AM

Nanologica Publishes Information Document Regarding Directed Share Issues and Rights Issue

Regulatory press release3/4/2026, 9:56 AM

BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN NANOLOGICA AB (PUBL)

Regulatory press release2/26/2026, 7:10 AM

Year-End Report 2025 Nanologica AB (publ)

Press release2/10/2026, 8:52 AM

Jeremie Trochu Proposed as New Board Member of Nanologica AB (publ)

Regulatory press release1/30/2026, 7:22 AM

NOTICE OF EXTRAORDINARY GENERAL MEETING IN NANOLOGICA AB (PUBL)

Regulatory press release1/30/2026, 7:16 AM

NANOLOGICA CARRIES OUT DIRECTED SHARE ISSUES OF APPROX. SEK 13.7 MILLION IN TOTAL, AND A FULLY SECURED RIGHTS ISSUE OF APPROX. SEK 82.5 MILLION

Regulatory press release1/29/2026, 5:07 PM

Nanologica AB (publ) Acquires Ardena Södertälje AB

Regulatory press release11/28/2025, 9:21 AM

Nanologica AB (publ) Receives Order of SEK 1.5 Million on a New Product

Press release10/24/2025, 7:13 AM

Redeye: Nanologica (Q3 update) - Production check, now positioned for ramp up

Regulatory press release10/23/2025, 6:10 AM

Interim Report Q3 2025 Nanologica AB (publ)

Regulatory press release10/22/2025, 7:41 AM

Nanologica AB (publ) Receives Order of appx. SEK 1 Million In China

Regulatory press release10/16/2025, 2:34 PM

Nanologica AB (publ) Receives Additional Order of approx. SEK 2.7 Million from Customer in the US

Regulatory press release10/14/2025, 9:53 AM

NANOLOGICA ANNOUNCES NOMINATION COMMITTEE FOR THE ANNUAL GENERAL MEETING 2026

Regulatory press release10/1/2025, 7:55 AM

Nanologica AB (publ) Enters the Insulin Market in China

Press release7/11/2025, 9:57 AM

Redeye: Nanologica Q2 2025 - Low near-term visibility but encouraging long-term case

Regulatory press release7/10/2025, 6:10 AM

Interim Report Q2 2025 Nanologica AB (publ)

Regulatory press release6/30/2025, 9:00 AM

Number of Shares and Votes in Nanologica AB (publ)

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.